Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 P16 093

Next Previous
Drug Profile

Gallium-68 P16 093

Alternative Names: [68Ga]P16-093; Ga-68 P16-093; HBED-CC-PHENOXY-PSMA; PSMA-093; PSMA-93

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Five Eleven Pharma
  • Developer Five Eleven Pharma; Indiana University; Peking Union Medical College Hospital
  • Class Radiopharmaceutical diagnostics
  • Mechanism of Action Emission-computed tomography enhancers; Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Prostate cancer
  • Phase I/II Glioma; Renal cancer

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Prostate-cancer(Diagnosis, Metastatic disease) in USA (IV, Injection)
  • 28 May 2025 No recent reports of development identified for phase-I development in Renal-cancer(Diagnosis, Metastatic disease) in USA (IV, Injection)
  • 27 Oct 2023 Five Eleven Pharma completes a phase I trial for Prostate and Renal cancer (Metastatic disease, Diagnosis) in USA (IV, Injection) (NCT03073395)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top